Compositions and methods for treating rheumatoid arthritis

A method of improving the physical function of a subject suffering from rheumatoid arthritis comprising administering an antibody, wherein:

• the antibody comprises the heavy chain variable region comprising the sequence SEQ ID NO:1 and the light chain variable region comprising the sequence SEQ ID NO:2,
• the antibody is administered subcutaneously at about 150 mg or about 200 mg once every two weeks to the subject,
• the subject is not administered with any other disease-modifying antirheumatic drug (DMARD) in course of administration with the antibody, and
• the subject was previously ineffectively treated for rheumatoid arthritis by administering at least one DMARD different from the antibody.

A method of improving the health related quality of life of a subject suffering from rheumatoid arthritis comprising administering an antibody, wherein:

• the antibody comprises a heavy chain variable region comprising sequence SEQ ID NO:1 and a light chain variable region comprising sequence SEQ ID NO:2,
• the antibody is administered subcutaneously at about 150 mg or about 200 mg once every two weeks to the subject,
• the subject is not administered with any other disease-modifying antirheumatic drug (DMARD) in course of administration with the antibody, and
• the subject was previously ineffectively treated for rheumatoid arthritis by administering at least one DMARD different from the antibody.

A method of treating rheumatoid arthritis in a subject comprising administering an antibody, wherein:

• the antibody comprises a heavy chain variable region comprising sequence SEQ ID NO:1 and a light chain variable region comprising sequence SEQ ID NO:2,
• the antibody is administered subcutaneously at about 150 mg or about 200 mg once every two weeks to the subject,
• the subject is not administered with any other Disease-Modifying AntiRheumatic Drug (DMARD) in course of administration with the antibody, and
• the subject was previously ineffectively treated for rheumatoid arthritis by administering at least one DMARD different from the antibody.